Novel glucose-lowering drugs for non-alcoholic fatty liver disease

BACKGROUND: The efficacy of novel glucose-lowering drugs in treating non-alcoholic fatty liver disease (NAFLD) is unknown. AIM: To evaluate the efficacy of glucose-lowering drugs dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose cotr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World J Diabetes
Hlavní autoři: Fu, Zuo-Di, Cai, Xiao-Ling, Yang, Wen-Jia, Zhao, Ming-Ming, Li, Ran, Li, Yu-Feng
Médium: Artigo
Jazyk:Inglês
Vydáno: Baishideng Publishing Group Inc 2021
Témata:
Meta-Analysis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7807257/
https://ncbi.nlm.nih.gov/pubmed/33520110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v12.i1.84
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky